Kornimate/medical-research-clean huggingface dataset:
covid-19 pediatric observatory

Conditions: COVID-19

Summary: in early december 2019, cases of pneumonia of unknown origin were reported in wuhan, hubei province in the people's republic of china. the disease spreads rapidly and the number of sick people is increasing. on january 3, 2020 a new virus of the coronavirus family is identified in samples of bronchoalveolar lavage fluid from a patient in wuhan and subsequently confirmed as the cause of these pneumonias. on 7 january 2020, the world health organization (who) designated it as the new coronavirus 2019 (i.e. 2019-ncov). on 11 february 2020, the who designated the disease associated with 2019-ncov as coronavirus 2019 disease (covid-19). on 12 march, who announced that the covid-19 outbreak is a pandemic. as of march 24, 2020, more than 375,000 cases of covid-19 had been diagnosed with more than 16,000 deaths attributed to this virus. (ref who https://www.who.int/emergencies/diseases/novel-coronavirus-2019 ). in france, the number of cases rose from 105 cases at the end of february to 19615 confirmed cases on march 24. (source public health france). most of the cases are adults. however, children are not completely spared and serious cases have been described. these severe cases can be respiratory or extra-respiratory (e.g. myocarditis). we also know that pediatric and adult cases differ in terms of clinical, biological and imaging findings, particularly chest ct scans. however, the description of paediatric pictures, especially severe forms and the involvement of children suffering from co-morbidities, remains poorly reported. finally, the risk factors for serious cases in children remain largely unknown. this observatory aim to describe the clinical phenotypes of hospitalized pediatric patients with covid19 in france, according to age groups. moreover for a subgroup of patients, informations regarding the long covid will be reported.


Eligibility criteria:
inclusion criteria: * children \< 18 years old * admitted in french pediatric wards * with a confirmed covid-19 infection. ( on nasal and pharyngeal swab specimens or blood samples tested positive for 2019-ncov nucleic acid using real-time reverse-transcriptase polymerase-chain-reaction (rt- pcr) assay; or on typical chest ct signs exclusion criteria: * expressed refusal to participate

Keywords: children pediatric department
scm muscle as a marker for frailty in patients undergoing ent surgery

Conditions: Frailty

Summary: this study focuses on evaluating the relationship between physical frailty and measurements of the muscles of the neck in patients undergoing non-cancer head and neck surgery.


Eligibility criteria:
inclusion criteria: • non-oncologic patients presenting for head and neck surgery with available neck ct scans. exclusion criteria: * patients undergoing cancer surgery * patients under18 years of age * patients without pre-surgical ct-scans of the head and neck
double blind placebo controlled study on the effect of extracorporal shock wave therapy on erectile dysfunction

Conditions: Erectile Dysfunction

Summary: this study aims to evaluate the effect of shockwave therapy on erectile dysfunction on patients responding to pde5i therapy in a sham controlled randomized double blind manner.

this study aims to evaluate the effect of a 12-session low intensity shockwave therapy protocol for patients with erectile dysfunction.

Eligibility criteria:
inclusion criteria: * ed of more than 6 months * rigidity score ≥ 3 under pde5i therapy * shim ≤21 under pde5i therapy * non- hormonal, neurological or psychological pathology * stable heterosexual relationship for more than 3 months exclusion criteria: * prior prostatectomy surgery * any unstable medical, psychiatric, spinal cord injury and penile anatomical abnormalities * clinically significant chronic hematological disease * anti-androgens, oral or injectable androgens * radiotherapy in pelvic region

Keywords: erectile dysfunction low intensity shock wave
predicting outcome following standardized exercise therapy in knee osteoarthritis patients

Conditions: Knee Osteoarthritis

Summary: pain sensitization has been associated with pain severity in people with knee osteoarthritis (koa) and a neuropathic pain component has been identified in up to 30% of koa patients. mechanistic pain profiling aims to identify the underlying mechanisms in the peripheral and central nervous systems, which are associated to the clinical pain. in addition, the mechanisms underlying the pain relieving effect of standardized exercise therapy are largely unknown, but it is hypothesized that they are linked to the patient's ability to activate the descending pain inhibitory pathways (conditioned pain modulation, cpm) in the central nervous system. mechanistic pain profiling including cpm have been used prognostic to identify responders to treatment, but these measures as a prognostic tool for standardized exercise therapy has not been investigated. the primary aim of this study is to investigate if mechanistic pain profiling alone or in combination with clinical pain measures before standardized exercise therapy can predict the patients' pain reduction following the exercise therapy program


Eligibility criteria:
inclusion criteria: * the american college of rheumatology for clinical knee osteoarthritis (excluding radiological oa assessment) exclusion criteria: * known factors to influence pain and pain sensitization
a multicenter active comparator study of hc-er in adults following bunionectomy surgery

Conditions: Postoperative Pain

Summary: the purpose of the study is to establish a dose-response relationship among several capsule strengths of hydrocodone bitartrate extended release (hc-er) and to compare the efficacy to placebo following bunionectomy surgery

sum of pain intensity differences (spid) for the primary pain measurement: vaspi (visual analog scale of pain intensity) from time 0 to 12 hrs; safety evaluations assessed: laboratory evaluations, physical examinations, vital signs/pulse oximetry and electrocardiography

Eligibility criteria:
inclusion criteria: * subject was able to read and voluntarily sign the institutional review board (irb) approved, written informed consent document and given the opportunity to ask questions regarding the study prior to the performance of any study- specific procedures. * subject required primary unilateral first metatarsal bunionectomy surgery with or without hammertoe repair with no other collateral procedures allowed * subject was male or female at least 18 years of age. * subject weighed \> or = 100 lbs (pounds). * subject was willing and able to comply with the protocol and able to score their pain intensity. * subject was in good health as determined by the investigator on the basis of medical history, physical examination, electrocardiogram (ecg) and screening laboratory results. * subject had not developed a condition or complications as result of the bunionectomy procedure that would preclude their participation in the study. * subject was willing and able to remain at the recovery day care center for the entire 24-hour treatment period. exclusion criteria: * subject was pregnant or lactating. * subject had been on an investigational drug within 30 days prior to the initiation of study drug. * subject had donated blood or blood components within one month prior to study (check-in). * subject had a know allergy or hypersensitivity to opioids, acetaminophen, and/or ketorolac. * subject had a known history of substance or alcohol abuse within 2 years prior to screening. * subject tested positive to drug screens (cocaine, marijuana, opioids, benzodiazepines, and barbiturates) that could not be justified by prescription use. * subject had a condition that would contraindicate the use of opioid analgesia (e.g., pulmonary disease or paralytic ileus). * subject had received a selective serotonin reuptake inhibitor (ssri), monoamine oxidase inhibitor (maoi) carbamazepine, quinidine, and/or tricyclic antidepressants (tca) compounds within 1-month prior to check-in. * subject had received opioids, tranquilizers, sedatives, or hypnotics within 48 hours prior to check-in. * subject had received corticosteroids, nonsteroidal anti-inflammatory drugs (nsaids), or other analgesics within 24 hours prior to check-in.
study of the safety and efficacy of tacrolimus ointment in treating chronic allergic contact dermatitis

Conditions: Dermatitis

Summary: a study of subjects with a known nickel allergy comparing tacrolimus to placebo, both associated with nickel patches to determine the safety and efficacy of treating chronic allergic contact dermatitis with tacrolimus ointment


Eligibility criteria:
inclusion criteria: * subject has a history of allergy to nickel exclusion criteria: * subject is pregnant or lactating * subject fails to react to the nickel disks (grade 0), reacts with a questionable (grade 1) or extreme (grade 4) reaction or the subject's reactions on the left and right arms are not of the same grade of intensity * subject has a known hypersensitivity to any component of the test medications * subject has any other significant dermatological condition that affects \>10% of the body surface area or general medical condition that could interfere with the study evaluation * subject has any significant medical condition that could compromise immune responsiveness

Keywords: chronic allergic contact dermatitis protopic
long-term outcomes for acute myeloid leukemia patients

Conditions: Acute Myeloid Leukemia

Summary: this international observational study aims at examining the patterns of health-related quality of life differences between long-term acute myeloid leukemia patients and their healthy peers from the general population.


Eligibility criteria:
inclusion criteria: * diagnosis of all subtypes of de novo aml, according to who criteria (at least 20% blasts in the bone marrow), except acute promyelocytic leukemia (apl). * age at aml diagnosis ≥ 18 years, * date of aml diagnosis at least 5 years before study enrollment, * aml-free status at study enrollment, * written informed consent provided. exclusion criteria: * major cognitive deficit or psychiatric problems hampering a self-reported evaluation, * not speaking and reading the language of the participating country, * more than 75 years at the time of study enrollment, * receiving any active treatment for aml at the time of study enrollment.
study of participants with crohn's disease and ulcerative colitis in eastern europe, middle east, and north africa (p08166)

Conditions: Inflammatory Bowel Disease; Crohn's Disease; Ulcerative Colitis

Summary: this study is being done to assess the clinical course and treatment options for crohn's disease (cd) and ulcerative colitis (uc) in the populations of eastern europe, middle east, and north africa.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of crohn's disease or ulcerative colitis.
prehospital translation of chest pain tools

Conditions: Acute Coronary Syndrome; Pulmonary Embolism

Summary: decision aids such as the heart pathway, emergency department assessment of chest pain score (edacs), revised geneva score and perc score have similar ability to accurately risk stratify emergency department (ed) patients with possible acute coronary syndrome (acs) and pulmonary embolism (pe) and have become standard practice in the ed setting. this study seeks to determine whether prehospital use of these decision aids is feasible and determine which are the most sensitive and specific for prediction of acs and pe, respectively.

to accomplish our specific aims the study team proposes a prospective, observational pilot study of four rapid risk stratification tools, the heart pathway score, edacs score, revised geneva score, and perc score, among 250 chest pain patients within two large ems systems. the proposed pilot study has broad-based support from local and state ems agencies, including cumberland and new hanover county ems agencies. each tool will be pilot tested and compared in the prehospital setting for feasibility and accuracy. paramedics will be trained in risk stratification tool use and then will prospectively collect the clinical data needed to calculate each risk stratification score when caring for adults with chest pain. completed paramedic risk assessments will be used to determine feasibility. patients will be followed for 30 days to determine occurrence of acs and pe events and the sensitivity of each risk stratification decision aid will be determined.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 21 * acute non-traumatic chest pain * transported by cumberland or new hanover county ems to a local emergency department exclusion criteria: * patients with evidence of st elevation myocardial infarction (stemi) on ecg * inter-facility transports (transfers) * patients with unstable vital signs * prisoners * non-english speakers
phase 2 study of efficacy and safety of ak120, in subjects with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.

this phase 2 study is designed to explore the efficacy and safety, as well as pharmacokinetics (pk), pharmacodynamics (pd) and immunogenicity of dose-ranging ak120 compared to placebo, which will generate information regarding the selection of dosing regimens with ak120 monotherapy treatment in adult subjects with moderate-to-severe ad. primary objectives: • to evaluate the efficacy of ak120 in the treatment of adult subjects with moderate-to-severe atopic dermatitis (ad). secondary objectives: * to evaluate the safety of ak120 in the treatment of adult subjects with moderate-to-severe ad. * to evaluate the pharmacokinetics (pk), pharmacodynamics (pd) and immunogenicity of ak120 in adult subjects with moderate-to-severe ad.

Eligibility criteria:
key inclusion criteria: 1. male or female, over the age of 18 2. chronic atopic dermatitis (ad) diagnosed at least 1 year. 3. subject with easi score ≥16, iga ≥ 3 (on the 0 to 4 iga scale, in which 3 is moderate and 4 is severe), ≥ 10% body surface area (bsa) of ad involvement. 4. subjects with a history of an inadequate response or medically inappropriate use of topical drug treatment within 6 months. key exclusion criteria: 1. inadequate washout period for prior drug therapy (eg. corticosteroids, immunosuppressive/ immunomodulating, biologics, phototherapy, chinese traditional medicine, anti-infective agents). 2. history of exposure to active tb, and/or history or current evidence of tb infection. 3. positive serology results at screening for hepatitis b, hepatitis c or hiv. 4. any history of vernal keratoconjunctivitis (vkc) or atopic keratoconjunctivitis (akc) within 6 months before the baseline visit. 5. history of clinical parasite infection, recent or planned travel to an area with endemic parasite infection within 6 months before the screening visit 6. any medical or psychiatric condition, laboratory, or ecg parameter which, in the opinion of the investigator or the sponsor's medical monitor, would place the subject at risk, interfere with participation in the study, or interfere with the interpretation of study results.

Keywords: atopic dermatitis monoclonal antibodies
arginine/omega-3 fatty acids/nucleotides nutritional supplement in treating patients with stage iii or stage iv head and neck cancer undergoing chemotherapy and radiation therapy

Conditions: Head and Neck Cancer

Summary: rationale: giving a nutritional supplement containing arginine, omega-3 fatty acids, and nucleotides to patients undergoing chemotherapy and radiation therapy may stimulate the immune system and help the body build a stronger immune response. purpose: this phase ii trial is studying how well an arginine/omega-3 fatty acids/nucleotides nutritional supplement works in treating patients with stage iii or stage iv head and neck cancer undergoing chemotherapy and radiation therapy.

objectives: * assess the effects of immunomodulator arginine/omega-3 fatty acids/nucleotides oral supplement (oral impact®) administered via percutaneous gastrostomy during adjuvant chemoradiotherapy in patients with stage iii or iv epidermoid head and neck cancer. outline: this is a multicenter study. patients undergo radiotherapy 5 days a week for 6½ weeks. patients receive cisplatin iv during weeks 1, 4, and 7 of radiotherapy. patients also receive arginine/omega-3 fatty acids/nucleotides oral supplement (oral impact®) via percutaneous gastrostomy tube 3 times daily for 5 days before each chemotherapy treatment.

Eligibility criteria:
disease characteristics: * diagnosis of head and neck cancer meeting the following criteria: * epidermoid carcinoma * stage iii or iv disease * must have percutaneous gastrostomy tube in place * must have undergone prior surgery for head and neck cancer within the past 6-8 weeks * no cerebral metastases patient characteristics: * who performance status (ps) 0-2 or karnofsky ps 60-100% * life expectancy \> 3 months * wbc \> 4,000/mm³ * anc \> 2,000/mm³ * platelet count \> 100,000/mm³ * ptt ≥ 50% * creatinine \< 130 μmol/l * not pregnant or nursing * fertile patients must use effective contraception * no severe sepsis * no requirement for parenteral nutrition * no pre-existing digestive pathology that results in bowel obstruction, nausea, vomiting, and/or abdominal pain \> grade 1 prior concurrent therapy: * see disease characteristics

Keywords: recurrent squamous cell carcinoma of the hypopharynx stage iii squamous cell carcinoma of the hypopharynx stage iv squamous cell carcinoma of the hypopharynx stage iii squamous cell carcinoma of the larynx stage iv squamous cell carcinoma of the larynx recurrent squamous cell carcinoma of the larynx recurrent squamous cell carcinoma of the lip and oral cavity stage iii squamous cell carcinoma of the lip and oral cavity stage iv squamous cell carcinoma of the lip and oral cavity recurrent squamous cell carcinoma of the nasopharynx stage iii squamous cell carcinoma of the nasopharynx stage iv squamous cell carcinoma of the nasopharynx recurrent squamous cell carcinoma of the oropharynx stage iii squamous cell carcinoma of the oropharynx stage iv squamous cell carcinoma of the oropharynx recurrent salivary gland cancer salivary gland squamous cell carcinoma stage iii salivary gland cancer stage iv salivary gland cancer
dermabond skin adhesives vs skin staples for closure of repeat cesarean section skin incisions

Conditions: Pregnancy

Summary: the use of dermabond skin adhesive vs. skin staples for the closure of repeat c-section incisions.

this research is interested in using dermabond skin adhesive as a closure for repeat cesarean incisions. the current standard of practice is to close these incisions with either skin surgical staples or suture. we will compare the use of dermabond vs. the use of skin surgical staples in the closure of these incisions. eightenn-50 year old pregnant patients are eligible for this study. other inclusion criteria are history of a previous pfannenstiel (transverse) incision and no evidence of infection at the incision site. exclusion criteria include a previous vertical incision and active infection at the incision site. patients will be enrolled during their prenatal appointments and the texas tech ob/gyn clinic, grand expectations, and the southwest ob/gyn associates offices. they will be consented by faculty, residents, and nursing staff. this is a preliminary study of 50 patients (25 in experimental arm, i.e. dermabond and 25 in the control group, i.e. surgical skin staples). patients will be randomized in a 1:1 fashion by placing the terms "dermabond" and "staples" in a sealed envelope. the envelopes will be kept in the family birth center under lock and key. the envelopes will be opened at the time of repeat c-section. a data set will be collected prior to randomization and include: gravidity, parity, age, bmi (weight and height), comorbid diseases and ethnic background. at the time of closure, there will be subcutaneous reapproximation of tissue to take the tension off of the skin. this will occur for all subjects. the type of suture used and the suturing technique will be recorded. the skin edges will be closed with either dermabond per label directions or with skin staples, depending on randomization. the length of the incision, the type of suture used, the type of stitch used and the total number of layers closed will also be documented. the number of staples will also be documented. during the hospital stay, the patients wound will be examined on post operative day one and three. at this time, wound characteristics will be documented using a modified hollander scale. a digital photograph of the incision will also be taken. the patient will also be given a patient satisfaction survey about their wound. the patients will then be seen at two weeks post partum and again at six weeks post partum. the wound characteristics and patient satisfaction will again be documented using the above materials. other data that will be collected includes the incidence of wound infection, as documented by wound culture, wound separation rates as documented by need for wound packing and wound dehiscence.

Eligibility criteria:
inclusion criteria: * pregant; between ages of 18-50; previous cesarean section with a transverse (sideways) skin incision. exclusion criteria: * previous vertical (up and down) skin incision; active infection at site of incison
international lung screen trial (ilst)

Conditions: Non-small Cell Lung Cancer; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Smokers at Risk of Lung Cancer

Summary: people who may be at increased risk of lung cancer due to age and smoking history will be invited to participate in this international study to determine the best way of using computed tomography (ct) of the chest to screen for early lung cancer. overseas data show that ct screening (screening tests can find diseases early, when they're easier to treat) can reduce deaths from lung cancer and this study will help determine who is most likely benefit from screening.

\[insert site name\]

Eligibility criteria:
* inclusion criteria: * women or men age from 55 to 80. * current or former smokers. a former smoker is defined as one who has stopped smoking for one or more years. * an estimated 6-year lung cancer risk of ≥1.51% based on the plcom2012 risk prediction model or ≥ 30 pack-years smoking history (pack-year is defined as number of pack of cigarettes smoked per day multiply by the number of years smoked. if a participant stopped smoking for 6 months or more and then restarted smoking again, the time will be subtracted from the total duration of smoking in 0.5 year increments) * ecog performance status 0 or 1. * capable of providing, informed consent for screening procedures (low dose spiral ct) * exclusion criteria * clinical symptoms suspicious for lung cancer e.g. hemoptysis, chest pain, weight loss * any medical condition, such as severe heart disease (e.g. unstable angina, chronic congestive heart failure), acute or chronic respiratory failure, home oxygen therapy, bleeding disorder, that in the opinion of the investigator could jeopardize the subject's safety during participation in the study or unlikely to benefit from screening due to shortened life-expectancy from the co-morbidities * have been previously diagnosed with lung cancer * have had other non-curatively treated cancer outside the lung. * pregnancy * pneumonia or bronchitis requiring antibiotic treatment within the last 12 weeks * unwilling to have a spiral chest ct * chest ct within 2 years * does not fit into ct scanner table due to gross obesity * cannot lie on ct scanning table on the back with arms over the head * received chemotherapy or cytotoxic drugs within the last 6 months * unwilling to sign a consent

Keywords: screening computed tomography lung cancer